Full Press Release Details
GAITHERSBURG, Md., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at NobleCon14 - Noble Capital Markets’ Fourteenth Annual Investor Conference, being held January 29-30, 2018 at the W Hotel, Fort Lauderdale, Florida.
| 14 th Annual Investor Conference Presentation Details | ||||
| Date: | Tuesday, January 30, 2018 | |||
| Time: | 2:30pm Eastern Time | |||
| Location: | W Hotel, Ft. Lauderdale, Florida, Studio 2 | |||
| Webcast: | http://noble.mediasite.com/mediasite/Play/6a0d0193d3f1470e9bf8607c7f1ba1161d |
A high-definition, video webcast of the presentation will be available the following day on the Company's web site www.altimmune.com and as part of a complete catalog of presentations available at Noble Capital Markets’ websites: www.noblecapitalmarkets.com, and www.nobleconference.com. You will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate. The webcast and presentation will be archived on the company's website and on the Noble websites for 90 days following the event.
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.
Email: enright@altimmune.com
Managing Director LifeSci Advisor
Email: arr@lifesciadvisors.com